Atrial flutter
Therapeutic area
Cardiology
Rare disease
No
- Definition
- A disorder characterized by an electrocardiographic finding of an organized, regular atrial rhythm with atrial rate of 240-340 beats per minute. Multiple P waves typically appear in the inferior leads in a saw tooth-like pattern between the QRS complexes. (CDISC)
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Atrial flutter
- Therapeutic area
- Cardiology
- atrial flutter
- atrial flutter
- atrial flutter (disease)
- All therapeutic areas
- Cardiology
- Severity
- Mild
- MONDO ID
- MONDO:0005310
- Parent condition
- MONDO:0005479
Related records
Broader conditions (7)
- Atrial tachycardia
- Cardiac rhythm disease
- Cardiovascular disorder
- Disease
- Disease by body system or component
- Heart disorder
- Human disease
Narrower conditions (1)
- Idiopathic neonatal atrial flutter
Trials (206)
- 30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event
- A Comparative Study Evaluating the Vein of MArshall Ethanol Infusion Ablation Using an Over-the-wire (OTW) Balloon Versus a microcatHeter in Patients With Atrial Fibrillation
- A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter
- A Randomized Trial of Contact Force in Atrial Flutter Ablation
- A Retrospective Analysis of the Use of ACE-inhibitors and Angiotensin Receptor Blockers
- A Retrospective Study of the Role of Thiazolidinediones to Reduce the Incidence of Atrial Arrhythmias
- A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke
- A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
- A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form
- A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation
- Ablating Atrial Tachycardias Occuring During Ablation of Complex Fractionated Electrograms in Persistent AF
- Ablation Index in Standard vs. High Power Radiofrequency Ablation for Typical Atrial Flutter: A Randomized Study (AITAF)
- Ablation of Typical Right Atrial Flutter
- Acute Atrial Fibrillation and Flutter Treated Electively
- ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression Study
- AIMIGo 12L ECG Synthesis Software Pivotal Study for Arrythmia Detection
- American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm
- Amiodarone to Prevent Post-Operative Arrhythmias
- An Initial Assessment of the Sphere-9™ Catheter and Affera Mapping and Ablation System
- Analysis of the Efficacy and Stability of a Wearable ECG Monitor
Approved drugs (2)
- Dofetilide
- Landiolol hydrochloride
Drugs in development (15)
- Amiodarone Phase 3
- Apixaban Phase 3
- Ascorbic acid Phase 3
- AZD1305 Phase 2
- Betrixaban Phase 2
- Celivarone Phase 2
- Dronedarone Phase 3
- Landiolol Phase 1
- Onabotulinumtoxina Phase 2
- Ramipril Phase 3
- Tedisamil sesquifumarate Phase 3
- Vanoxerine Phase 2
- Vernakalant Phase 2
- Vernakalant hydrochloride Phase 3
- Warfarin Phase 3